• Skip to primary navigation
  • Skip to main content
  • Skip to footer
MotherToBaby

MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

Hide Search
Shopping Cart
Show SearchSearch
866.626.6847
  • About
    • Our Work
    • Our Team
    • Our Partners
    • Our Impact
  • Exposures
    • Pregnancy and Breastfeeding Exposures
    • Fact Sheets
    • Baby Blogs
    • Podcasts
    • Interactive Tool
    • Other Educational Tools
    • LactRx App
  • Studies
    • Ongoing Studies
    • What’s Involved?
    • Join Now
    • Refer a Patient
    • Health Providers
    • Pharma Industry
    • Publications
  • Health Professionals
    • Patient Education and Provider Resources
    • Refer a Patient
    • Request Materials
    • Meetings
    • FAQs
    • OTIS Membership
  • Media
    • Media Requests
    • Press Releases
    • eNews Sign Up
  • In Your Area
  • OTIS
    • About OTIS
    • OTIS Membership
    • Annual Meeting
    • Member Log-In
  • Donate
  • Contact
  • Show SearchSearch

Lysergic Acid Diethylamide (LSD)

May 1, 2024

Selected References:

  • Aase JM, et al. 1970. Children of mothers who took LSD in pregnancy. Lancet 1:100-1.
  • Baquiran M, et al. 2023. Lysergic acid diethylamide toxicity. [Updated 2023 Dec 17]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553216/
  • Cohen MM, et al. 1968. The effect of LSD-25 on the chromosomes of children exposed in utero. Pediat Res 2:486-492.
  • Das, Saibal et al. Lysergic acid diethylamide: a drug of ‘use’?. Therapeutic advances in psychopharmacology 6,3 (2016): 214-28.
  • Fabro S, Sieber SM. 1968. Is lysergide a teratogen? Lancet 1(7543):639.
  • Fuentes, Juan & Fonseca, Francina & Elices, Matilde & Farré, Magí & Torrens, Marta. (2020). Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Frontiers in Psychiatry. 10. 943. 10.3389/fpsyt.2019.00943.
  • Jacobson CB, Berlin CM. 1972. Possible reproductive detriment in LSD users. JAMA 222(11):1367-1373.
  • Haden, M, & Woods, B. 2020. LSD overdoses: three case reports. Journal of Studies on Alcohol and Drugs, 81(1), 115-118.
  • Long SY. 1972. Does LSD induce chromosomal damage and malformations? A review of the literature. Teratology 6(1):75-90.
  • McElhatton PR. 2000. Fetal effects of substances of abuse. J Toxicol Clin Toxicol; 38:194-5.
  • McGlothlin WH, et al. 1970. Effect of LSD on human pregnancy. JAMA. 1; 212(9):1483-7.
  • Mueller, B. A., Daling, J. R., Weiss, N. S., & Moore, D. E. (1990). Recreational drug use and the risk of primary infertility. Epidemiology (Cambridge, Mass.), 1(3), 195–200
  • Papac DI and Foltz RL. 1990. Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol. 14(3):189-90.
  • Robinson JT, et al. 1974. Chromosome aberrations and LSD. A controlled study in 50 psychiatric patients. J Psychiatry. 125(0):238-44

Footer

               

Hot Links

  • Home
  • Exposures
  • Fact Sheets
  • Baby Blogs
  • Podcasts
  • Pregnancy Studies
  • Join a Study Now
  • Healthcare Professionals
  • Refer a Patient
  • Request Materials
  • News
  • Donate
  • Ask An Expert

Current Studies

  • Ankylosing Spondylitis
  • Constipation
  • Coronavirus (COVID-19)
  • Eczema (Moderate-to-Severe)/Atopic Dermatitis
  • Hidradenitis Suppurativa
  • Lupus
  • Multiple Sclerosis
  • Non-Radiographic Axial Spondyloarthritis
  • Psoriasis
  • Psoriatic Arthritis

Contact

Exposure Information Service
866.626.6847

Pregnancy Studies
877.311.8972

Media Inquiries
619.368.3259
nchavez@mothertobaby.org

MotherToBaby, a service of the Organization of Teratology Information Specialists

Copyright © 2025 The Organization of Teratology Information Specialists

  • Accessibility
  • Privacy
  • Terms
  • Site Map
^

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.